Drug profile · INN
sacubitril
ENTRESTO
sacubitril (ENTRESTO) is a neprilysin inhibitor. Route of administration: oral. Current US regulatory status: approved.
FDA: approved EMA: approved Cardiovascular system (C09) C09DX04
US status approved
Patents linked 1
Pipeline programs 4
News articles 0
Drug details — sacubitril
- US status
- approved
- Class
- Cardiovascular system (C09)
- Route
- ORAL
- Patents
- 1
- Programs
- 4
- Data quality
- 0.84
Quick answer
sacubitril (ENTRESTO) is a neprilysin inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN sacubitril
Brand ENTRESTO
Mechanism Neprilysin inhibitor
Target Neprilysin
Therapeutic class Cardiovascular system (C09)
Route ORAL
Formulation CAPSULE, PELLETS
ATC code C09DX04
Mechanism of action
Neprilysin inhibitor
Primary target: Neprilysin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is sacubitril?
sacubitril (ENTRESTO) is a neprilysin inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sacubitril?
ENTRESTO is a marketed brand name for sacubitril. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sacubitril?
sacubitril has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.